Hepatitis News
-
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
-
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the agreement, $50 million is ...
-
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of ...
-
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 22, 2022 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ...
-
VBI Vaccines to Participate in the Jefferies Healthcare Conference
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022. Presentation Details Event: Jefferies Healthcare Conference ...
-
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral presentation at The International Liver ...
-
Versius adopted for urological procedures in Pakistan
CMR Surgical – the global surgical robotics business – has today announced the successful completion of high-volume urological procedures at the Sindh Institute of Urology and Transplantation (SIUT) using the next generation surgical robotic system, Versius®, in Pakistan. SIUT is a renowned, charitable institute, providing free state of the art medical treatment to all patients, ...
-
Neuropathix, Inc. Receives Patent Grant from India for its Novel Anti-Inflammatory Compounds
DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the Company has been issued Indian Patent IN201617027528 specific to its global patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their ...
-
The new Walloon company Cellaïon makes its first closing
Cellaïon, a Walloon biotechnology company created by a consortium of Belgian-Luxembourg investors, announces its first closing following the acquisition of the assets of Promethera and its HepaStem® technology platform. The consortium led by Fund Plus (Leuven, Belgium) is also composed of SMS Investments SA (Luxembourg), Sopartec (UCLouvain Technology Transfer Office, Louvain-la-Neuve, ...
By Cellaïon
-
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics ...
-
Mempro™ Plant-based Virus-like Particle Production Now Available at Creative Biostructure
Creative Biostructure, a biotech company that specialized in providing cost-effective contract services to both academia and pharmaceutical industries in the field of structural biology, now offers VLP production services with various types of plants. VLPs carrying the desired membrane proteins are known as lipid particles, which are widely used to produce integral membrane proteins. Lipid ...
-
A Complete Overview of a Life Saving Treatment - Liver Transplantation in India
Hepatic transplant or liver transplant is a treatment that includes the replacement of diseased liver with the healthy liver from another individual. It is a surgical treatment to remove the non-functional liver (liver failure) and replace it with the healthy liver (from a deceased donor) or a part of the healthy liver (from a living donor). Few important matters regarding liver transplantation ...
-
Towards a cure for Mycobacterium abscessus disease using inhaled tigecycline
Roden — July 7, 2021 — Mycobacterium abscessus is a nontuberculous mycobacterium (NTM) that primarily causes severe pulmonary infections. The pathogen is also known as the ‘antibiotic nightmare’, due to its resistance to nearly all antibiotics. Following successful research into a potential treatment option, PureIMS, Radboudumc and Sever Pharma Solutions (until recently ...
By Pureims B.V.
-
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued patents in Switzerland (CH), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Italy (IT), Spain (ES), Belgium (BE), Sweden (SE), ...
-
Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol "KLFE"
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, brings proven cannabinoid R&D to the public by officially commencing trading on the OTC Markets under the ticker symbol “KLFE.” The Company previously had a registration statement on Form S-1 go ...
-
Glycotest™ Closes $10 Million Series A Financing with Fosun Pharma
Glycotest Inc., Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today the close of a Series A funding round of $10 million from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”). The transaction includes an equity investment of an initial tranche of $3 million with the remaining $7 ...
-
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to ...
-
Glycotest Innovator Joins the Medical University of South Carolina as the New SmartState Endowed Chair of Proteomic Biomarkers
Glycotest, Inc. innovator Professor Anand Mehta, a leader in the development of glycoproteomic technologies for the discovery of novel cancer biomarkers, joins the Medical University of South Carolina (MUSC) and Hollings Cancer Center, Charleston, SC, as the new SmartState Endowed Chair of Proteomic Biomarkers, the company announced today (see MUSC). Mehta, whose work has resulted in 79 ...
-
D-Kimia expands to further support North American Market
D-Kimia Diagnostic Solutions announces the opening of its offices in New York to support its growing partnerships with US diagnostic labs and further develop its companion testing solutions with major anti-viral treatments. Hepatitis C (HCV) affects an estimated 5 million Americans and there is a growing concern of a much larger undiagnosed population. The CDC now recommends all baby boomers ...
By D-Kimia, LLC
-
AUC Launchs First University Spinoff Company in Egypt
The American University in Cairo (AUC) announced today, in a press conference held on Tahrir Square campus, the launch of Egypt’s first University spinoff company. The company, D-Kimia, develops novel and affordable diagnostic solutions to detect a broad range of diseases, initially focusing on the identification of the hepatitis C virus (HCV) that affects over 170 million people worldwide. ...
By D-Kimia, LLC
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you